trial

Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities

NCTId NCT02751307
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 55 (actual)
Sponsored by Taipei Medical University Shuang Ho Hospital
Primary completion 2015-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
55 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-05
Primary completion
2015-01
Eligibility
ALL · 20 Years · 65 Years

Interventions & indications

Drugs
metformin 500 mgClozapine

Sponsors

Taipei Medical University Shuang Ho HospitalLead Sponsor
Taipei City HospitalCollaborator

Investigators

1
Chun-Hsin Chen, MDPrincipal Investigator

Sites

0 total

Facts & assertions

4 sourced
Enrollment
55
Phase
PHASE4
Primary Completion Date
2015-01
Status
COMPLETED
relationships
The graph out of here
drug
metformin 500 mg
drug
Clozapine
drug
lead_sponsor
Taipei Medical University Shuang Ho Hospital
company
collaborator
Taipei City Hospital
company
indication
Metabolic Syndrome
indication
Schizophrenia
indication
Metabolic Syndrome
indication
investigator
Chun-Hsin Chen, MD
person